Evidence map›Paper›PMID 41028666›Full record

ArticleIrish journal of medical science2025

An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.

Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephanie BoweSouth Infirmary, Victoria University Hospital, Cork, Ireland. drstephaniebowe@gmail.com.ORCID http://orcid.org/0000-0002-4958-820X
Michelle MurphySouth Infirmary, Victoria University Hospital, Cork, Ireland.
John BourkeSouth Infirmary, Victoria University Hospital, Cork, Ireland.
Caitriona RyanInstitute of Dermatologists, Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.

methodsAn electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.

resultsIn total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).

conclusionIn general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.

Indexed as

Dermatologic AgentsDermatologistsNeoplasmsPractice Patterns, Physicians'PsoriasisConsultantsDermatologyFemaleHumansIrelandMaleMethotrexateSurveys and QuestionnairesThalidomideapremilastDermatologic AgentsMethotrexateThalidomideBiologic therapyMalignancyMedical dermatologyPsoriasis

Identifiers

PMID41028666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.